Alprostadil as an Adjuvant Therapy With Indirect Angiosomal Revascularization in Critical Limb Ischemia.
Status:
Not yet recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess the efficacy of Alprostadil (Prostaglandin E2) as adjuvant
therapy after failure of direct but indirect angiosomal revascularization in patients with
critical limb ischemia.